100 Participants Needed

Web-Based Tool for Cardiovascular Care in Prostate Cancer

MD
Overseen ByMatthew Doyle
Age: 18+
Sex: Male
Trial Phase: Academic
Sponsor: Vivek Narayan
Must be taking: ADT
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a web-based tool called the CARE-PC Web-Based Application, designed to help men with prostate cancer undergoing androgen deprivation therapy (ADT) understand and manage their heart health. The goal is to improve patient awareness of personal heart risks and provide ways to reduce those risks. Men with prostate cancer who are currently on ADT or will be on it for at least six months are suitable candidates for this trial. Participants will use the tool to learn about their cardiovascular risks and assess its impact on their care.

As an unphased trial, this study offers participants the chance to contribute to innovative research that could enhance heart health management for men with prostate cancer.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What prior data suggests that this web-based tool is safe for cardiovascular education in prostate cancer patients?

Research has shown that the CARE-PC web app helps men with prostate cancer understand their risk of heart problems. This tool educates users about heart health risks and offers advice on reducing them.

Regarding safety, the app serves purely for learning and information. It doesn't involve taking new medications or undergoing medical procedures, so it poses no physical side effects or risks.

The main goal of this tool is to help prostate cancer patients better understand and manage their heart health. As an educational tool, it is considered very safe for participants.12345

Why are researchers excited about this trial?

Researchers are excited about the CARE-PC Web-Based Application because it offers a novel approach to managing cardiovascular health in men with prostate cancer undergoing androgen deprivation therapy (ADT). Unlike traditional treatments which primarily focus on hormone levels, this web-based tool provides personalized cardiovascular care by integrating digital health monitoring and patient education. By leveraging technology, it aims to empower patients to actively participate in their care, potentially improving overall health outcomes and quality of life. This innovative approach could set a new standard in supportive care for prostate cancer patients.

What evidence suggests that this web-based tool is effective for improving cardiovascular care in prostate cancer patients?

Research shows that online tools like the CARE-PC app can help patients better understand their heart health risks. In this trial, the CARE-PC app educates prostate cancer patients about their heart risks while on androgen deprivation therapy (ADT). Early results suggest that digital health tools can help patients manage these risks by providing personalized information and advice. Studies have found that when patients understand their health risks, they are more likely to take steps to reduce them. Overall, the CARE-PC app could play an important role in helping prostate cancer patients maintain heart health.12367

Who Is on the Research Team?

Vivek K. Narayan, MD, MS profile ...

Vivek K. Narayan

Principal Investigator

University of Pennsylvania

Are You a Good Fit for This Trial?

This trial is for men over 18 with prostate cancer who are currently on or will start androgen deprivation therapy (ADT) for at least six months. Participants need to be able to read and understand English.

Inclusion Criteria

Patients must be able to read and understand English.

Exclusion Criteria

n/a

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Web-Based Application Participation

Participants use a web-based tool to learn about cardiovascular risks and receive individualized risk estimates and mitigation recommendations

6 months
Online participation

Follow-up

Participants are monitored for changes in cardiovascular care and medication adjustments

18 months

What Are the Treatments Tested in This Trial?

Interventions

  • CARE-PC Web-Based Application
Trial Overview The CARE-PC study is testing a web-based application designed to educate prostate cancer patients about their cardiovascular risks associated with ADT, provide personalized risk assessments, and offer guidelines for risk reduction.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: Men With Prostate Cancer Planned for Receiving ADTExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Vivek Narayan

Lead Sponsor

Trials
1
Recruited
100+

National Comprehensive Cancer Network

Collaborator

Trials
121
Recruited
7,400+

Published Research Related to This Trial

The Composite Holistic Needs Assessment Adaptive Tool-Prostate (CHAT-P) was developed through a collaborative process involving men with prostate cancer and healthcare professionals, ensuring it meets the specific needs of patients and enhances cancer care delivery.
Initial testing with 16 patients showed that CHAT-P is user-friendly and acceptable, empowering men to communicate their concerns effectively before consultations, while also identifying critical psychological issues and symptoms that require urgent attention.
A Web-Based Prostate Cancer-Specific Holistic Needs Assessment (CHAT-P): Multimethod Study From Concept to Clinical Practice.Nanton, V., Appleton, R., Ahmed, N., et al.[2022]
Eighteen Australian men with metastatic prostate cancer expressed a need for better understanding and support regarding exercise, with many not discussing it with their healthcare providers, highlighting a gap in communication and education.
Participants found a proposed web-based exercise intervention acceptable due to its affordability and convenience, emphasizing the importance of user-friendly design and professional support for effective implementation.
Examining the Priorities, Needs and Preferences of Men with Metastatic Prostate Cancer in Designing a Personalised eHealth Exercise Intervention.Evans, HEL., Forbes, CC., Vandelanotte, C., et al.[2022]
In a study of 511 prostate cancer patients, only 16% reported searching for information about their condition online, highlighting a gap in Internet use among this population.
Younger and more educated men were more likely to use the Internet for health information, suggesting that access to online resources may contribute to social inequalities in healthcare information access.
The Internet and prostate cancer patients: searching for and finding information.Buntrock, S., Hopfgarten, T., Adolfsson, J., et al.[2018]

Citations

Study Details | NCT06064149 | The CArdiovascular Risk ...The CARE-PC app is a pragmatic, patient-oriented, web-based application that enables the education of patients regarding cardiovascular (CV) risks and collects ...
Web-Based Tool for Cardiovascular Care in Prostate CancerTrial Overview The CARE-PC study is testing a web-based application designed to educate prostate cancer patients about their cardiovascular risks associated ...
Assessment of a Web-based Cardiovascular Risk Tool in ...The web-based tool educates patients of CV risks in prostate cancer and to inform them of individualized, estimated CV risk and guideline-based risk mitigation ...
Effectiveness of electronic patient reporting outcomes, by a ...The benefits of Electronic Patient -Reported Outcomes (e-PRO) for telemonitoring are well established, allowing early detection of illnesses and continuous ...
The CArdiovascular Risk Evaluation in Men with Prostate ...This protocol will 1) test the feasibility and acceptability of the CARE-PC web-based application and its impact on prostate cancer patient perceptions of CV ...
Predicting Cardiovascular Risk in Patients with Prostate ...Prostate cancer patients receiving newer hormone treatments (abiraterone or enzalutamide) face an increased risk of heart problems, ...
Abstract 4140247: Place and Race in Cardiovascular ...Men with prostate cancer (PC) frequently die of cardiovascular disease (CVD). Rurality has shown to increase adverse outcomes in PC men. 26 ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security